Equitable Trust Co. Sells 1,580 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Equitable Trust Co. lowered its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 10.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,885 shares of the medical equipment provider’s stock after selling 1,580 shares during the quarter. Equitable Trust Co.’s holdings in Lantheus were worth $1,153,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the company. Signaturefd LLC raised its holdings in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares during the period. UMB Bank n.a. raised its holdings in shares of Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 126 shares during the last quarter. Bleakley Financial Group LLC raised its holdings in shares of Lantheus by 6.1% in the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock worth $200,000 after acquiring an additional 129 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Lantheus by 45.5% in the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after acquiring an additional 146 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Lantheus in the 3rd quarter worth about $25,000. Institutional investors own 99.06% of the company’s stock.

Insider Activity

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group assumed coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. JMP Securities restated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Finally, Truist Financial restated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Stock Performance

NASDAQ:LNTH opened at $86.91 on Tuesday. The firm has a market cap of $6.04 billion, a price-to-earnings ratio of 14.46 and a beta of 0.44. Lantheus Holdings, Inc. has a 52 week low of $54.69 and a 52 week high of $126.89. The firm has a 50-day moving average price of $92.02 and a two-hundred day moving average price of $98.46.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.